Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

M701

Phase 3Small molecule

WWuhan YZY Biopharma Co., Ltd.

M701 is one of 91 small molecule programs targeting Ascites. It is currently in Phase 3.

3

Indications

3

Total Trials

2

Active Trials

90

Competitors

Pipeline

Status by Indication[3][1]

Indication

AscitesActive, not recruiting

Pleural EffusionActive, not recruiting

Ovarian CancerActive, not recruiting

AscitesPhase 3

Active, not recruiting

Pleural EffusionPhase 1/Phase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Votrient

Novantrone

Trodelvy

Jemperli

GGlaxo Dba Glaxosmithkline

Pamiparib

Tylenol

Trastuzumab Deruxtecan

AK104

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Malignant Pleural Effusions

NCT05543330

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Completed·WWuhan YZY Biopharma Co., Ltd.·Phase 2·NCT06266091·115 enrolled

Ascites1 trial

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Active, not recruiting·WWuhan YZY Biopharma Co., Ltd.·Phase 3·NCT06432296·312 enrolled

Malignant Pleural Effusions1 trial

A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of M701, a Recombinant Epcam and CD3 Bispecific Antibody , in Patients With Malignant Pleural Effusions Caused by NSCLC

Recruiting·WWuhan YZY Biopharma Co., Ltd.·Preclinical·NCT05543330·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for M701. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — M701 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for M701. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wuhan YZY Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWuhan YZY Biopharma Co., Ltd.

Related News